Research entry · Not admitted

Theranos

This is a research-stage projection. It is not admitted. Source attribution does not establish independent corroboration. Inspect

Research dossier, timeline and source context. The original research material remains available for inspection.

Theranos, Inc. was a blood-testing company that claimed its Edison device could perform hundreds of clinical assays on a small fingerstick sample. Between 2013 and 2016, the company offered retail testing through Walgreens locations while raising more than $700 million from investors, according to SEC complaint allegations. The Ninth Circuit's 2025 amended opinion, affirming criminal convictions on appeal, noted that only twelve assays were ever run on Edison at scale, with remaining patient tests processed on modified or unmodified third-party analyzers, and that CMS inspection identified condition-level deficiencies constituting immediate jeopardy to patient health.

The adjudicative record contains multiple legally distinct outcomes that a summary of the case cannot compress without error. Elizabeth Holmes was convicted of investor-fraud conspiracy and three substantive wire-fraud counts while being acquitted on patient-fraud charges; Ramesh Balwani, tried separately, was convicted on all counts including patient-fraud conspiracy. Holmes settled parallel SEC civil charges without admitting or denying the complaint's allegations. As of mid-2026, a certiorari petition by Balwani remained pending before the Supreme Court, making the appellate record final for Holmes but still open for her co-defendant.

Scope

Theranos, Inc.'s blood-testing business and technology claims, especially the 2013–2016 retail-testing period; regulatory findings concerning its clinical laboratory; civil securities enforcement; federal criminal prosecutions of Elizabeth Holmes and Ramesh "Sunny" Balwani; the different verdicts returned by separate juries; sentencing/restitution; and appellate review.

This dossier is not a biography of Elizabeth Holmes, a complete corporate history of Theranos, or a general page about medical-device regulation.

Key distinctions

"Theranos test" is not one technological object. Patient samples were processed on Theranos-developed Edison devices, modified third-party commercial analyzers, and unmodified third-party analyzers. The miniLab was a separate development-stage system.

"Fingerstick testing" does not imply "tested on a Theranos proprietary analyzer." A fingerstick sample could be collected in a Theranos nanotainer and then run on an Edison or modified third-party machine.

A published testing menu is not a device-capability list. Theranos advertised/offered a broad test menu, while the Ninth Circuit record says only twelve assays were ever run on the Edison.

FDA clearance of one assay is not FDA validation of the whole platform. FDA's K143236 record shows a Theranos HSV-1 IgG assay received a 510(k) substantially-equivalent decision; it does not establish that the Edison could accurately perform the entire advertised menu.

SEC complaint ≠ SEC adjudicated merits finding. Holmes and Theranos settled SEC charges without admitting or denying the allegations.

Criminal indictment ≠ conviction.

Holmes verdict ≠ Balwani verdict. The two defendants were tried separately and juries reached materially different patient-fraud outcomes.

Acquittal ≠ affirmative factual finding that patient tests were accurate or that no patient was harmed.

CMS regulatory "immediate jeopardy" finding ≠ criminal fraud verdict.

Sentencing narrative / government characterization of trial evidence ≠ jury finding on every described event.

Court-hosted trial exhibit ≠ judicial finding. A Theranos document remains a Theranos-authored document even when preserved on cand.uscourts.gov.

Analysis

Theranos is a near-perfect test of adjudicative posture discipline.

A conventional summary easily compresses all of the following into "Theranos was fraud":

Counterpedia should make those objects visually and graphically impossible to confuse.

a company claim;

an internal or first-party document;

an SEC allegation;

an SEC settlement without admission;

a CMS regulatory deficiency finding;

a criminal indictment;

trial evidence;

a guilty verdict;

an acquittal;

a dismissed count;

a hung count;

a sentence;

Temporal bounds

Primary demo period: 2010–2026, with emphasis on:

2013–2015 retail testing / fundraising;

2015–2016 CMS/FDA regulatory period;

2018 SEC and criminal charging;

2021–2022 trials and verdicts;

2022 sentencing;

2025 Ninth Circuit opinion and amended opinion;

2026 pending Supreme Court petition by Balwani.

Questions in the research record

C-1 — "Theranos was charged" vs "Theranos/Holmes admitted fraud" · question / dispute
C-2 — Holmes verdict vs Balwani verdict · question / dispute
C-3 — Patient-test problems vs Holmes's patient-count acquittals · question / dispute
C-4 — "Theranos testing" denominator problem · question / dispute
C-5 — "The technology was fake" vs specific FDA clearance · question / dispute
C-6 — CMS regulatory finding vs fraud finding · question / dispute
C-7 — Trial exhibit vs judicial finding · question / dispute
C-8 — Appellate opinion source-version drift · question / dispute
C-9 — "Affirmed" vs "final beyond further review" · question / dispute

Record provenance

research_artifact: {"pack_id":"demo-corpus-twelve","artifact_slug":"theranos-demo-corpus-dossier-v0-1","artifact_sha256":"a3be17c5847c47edf19f04b46cbc6aaef464cfb98192273ecb9aed04e400058e","source_href":"/research/demo-corpus-twelve/theranos-demo-corpus-dossier-v0-1","source_kind":"dossier"}

Projection axes

Postureresearch

Source kindresearch_template

Source surfacenot supplied

This renderer preserves upstream distinctions; it does not mint identity, support, authenticity, admission, or truth.

INSPECTCounterpedia Check · this read modelInspect only the signals this renderer actually received

Record identifier: research:demo-corpus-twelve:theranos-demo-corpus-dossier-v0-1
Posture: research
Source kind: research_template
Lifecycle: not recorded
Source footprint: not supplied to this presentation
Capture associations: not evaluated here
Unresolved capture identity: not evaluated here
Truth: not a finding of this renderer
Authenticity: not inferred from source or capture presence
Research profile: Demo Corpus
Artifact kind: dossier
Source candidates: 18

CHECK is inspection, not a truth badge. Source presence ≠ support; capture association ≠ authenticity; rendering ≠ admission.